Over the past decade the phosphoinositide-3 kinase (PI3K) signaling pathway emerged as an important player for tumor initiation and growth and, currently, PI3K inhibition constitutes a promising therapeutic approach for solid and hematological tumors. Beside its role in tumor cell evolution, PI3K signaling also provides integral functions for noncancerous cells that reside in healthy tissues surrounding the tumor, also referred as tumor microenvironment (TME). This review will address how PI3K signaling participates to the tumorigenic process and discuss the interaction between tumor cells and the surrounding TME, with particular focus on the role of PI3Ks in tumor-associated immune responses, tumor angiogenesis and metastasis formation.
INTRODUCTION
The phosphoinositide-3 kinase (PI3K) signaling pathway is one of the most frequently deregulated signaling cascades in tumor initiation and progression. PI3K enzymes are crucial effectors of a broad range of extracellular stimuli and mediate activation of signal transduction events regulating cell survival, morphology and migration of malignant and non-malignant cells.
Among the three identified classes of PI3Ks, class I is the most intensively characterized and includes four different isoenzymes, called PI3Ka, PI3Kb, PI3Kd and PI3Kg, all composed by a p110 catalytic and a regulatory subunit. While all member of class IA, PI3Ka, PI3Kb, PI3Kd, share the same isoforms of regulatory subunit, p85a, p55a, p50a, p85b and p55g, the unique member of class IB, PI3Kg binds to either p101 or p84/87 regulatory adaptors. Although class I PI3Ks exert a common lipid kinase activity by producing the second messenger phosphatidylinositol-3-trisphosphate, PtdIns(3,4,5)P3, their activation varies according to the type of stimulus. PI3Ka and PI3Kd are triggered following translocation to the plasma membrane upon tyrosine kinase receptors activation. On the other hand, PI3Kg is mainly engaged and activated by G-protein-coupled receptors (GPCRs). Conversely, PI3Kb is, so far, the only PI3K isoform responding to both tyrosine kinase receptors and GPCRs. Following receptor stimulation, PI3Ks catalyze the production of PtdIns(3,4,5)P3, which acts as a docking site for a plethora of intracellular effectors, including Akt/PKB, 3-phosphoinositide-dependent kinase and Bruton's tyrosine kinase, thus regulating proliferation, survival and migration. [1] [2] [3] Alterations in the PI3K signaling pathway promote growth and progression of a variety of human tumors, including glioblastomas (GBM), breast, colon and endometrial cancers. [4] [5] [6] In addition, aberrant activation of the PI3K axis can predict aggressive disease and poor prognosis [7] [8] [9] as well as correlate with resistance to chemo-and radio-therapy. [10] [11] [12] [13] [14] [15] One of the most common genetic alterations of the PI3K signaling pathway occurring in human cancer is the loss or inactivation of the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) tumor-suppressor gene, which antagonizes PI3K activity by converting the PI3K lipid product, PtdIns(3,4,5)P3, into PtdIns(4,5)P2. 16, 17 Hence, PTEN loss leads to intracellular accumulation of PtdIns(3,4,5)P3, with consequent activation of downstream components of the PI3K signaling pathway. 18, 19 Genetic inactivation or reduced expression of PTEN frequently occurs in GBM, endometrial, lung and breast cancers.
14 Genomic deletions of PTEN have also been found in 68% of primary prostate cancer and in 23% of high-grade prostatic intra-epithelial neoplasia. 20 Additionally, as documented for the invasive ductal breast carcinoma, PTEN loss often associates with poor prognosis, representing a predictive factor of treatment failure. [21] [22] [23] Mutational profiling of several tumors, including breast, endometrial cancers and GBMs, has revealed the presence of somatic mutations in the p110a coding gene, PIK3CA. [24] [25] [26] [27] Two hot spot regions have been identified in exons 9 and 20, corresponding to the catalytic and the helical domain, respectively. 24, 27 PIK3CA mutants have been demonstrated to enhance the activation of downstream signaling molecules even in the absence of growth factor stimuli. 28, 29 The mutational status of PIK3CA gene strictly correlates with poor prognosis and outcome in breast cancer, as demonstrated by two independent clinical studies. 30, 31 Together with PIK3CA alterations, mutations in the p85 regulatory subunit coding gene (PIK3R1) have also been reported in a variety of human tumors, including GBMs, ovarian, endometrial and colorectal cancers. This communication has been clearly represented in the past by the 'seed and soil' hypothesis conceived by Stephen Paget, where cancer cells represent the 'seed' and tissue microenvironment supply the 'soil'. 42, 43 In this context, during tumor progression, malignant cells induce the formation of a cellular milieu favoring growth and dissemination and bearing an influence over cancer diagnosis and therapy. 44 The stromal compartment surrounding the tumor is heterogeneous and consists of cancer-associated fibroblasts (CAFs), endothelial cells, neutrophils, macrophages, T and B lymphocytes, mastocytes, natural killer (NK) cells and dendritic cells. PI3Ks are expressed in all these cell types where they can mediate a cross-talk with tumor cells (Figure 1) . Therefore, PI3Ks not only exert their activity to drive cell growth and sustain survival inside cancer cells but also to modulate microenvironmental changes. Within stromal cells, these enzymes apparently contribute to steering the response to a multitude of cues that cancer cells produce to modify their microenvironment (Table 1) .
PI3K SIGNALING AND TUMOR-ASSOCIATED IMMUNE RESPONSE
Immune cells and mediators are fundamental components of TME. Depending on the cell type involved, the immune response can have either pro-or anti-tumorigenic functions. Notably, cytotoxic T lymphocytes, T helper and NK cells are able to recognize and destroy tumor cells as well as circulating tumor metastases, a process known as immune surveillance. Their presence in the TME is thus largely recognized as a factor of good prognosis. 45 Conversely, cells normally involved in chronic inflammation, such as monocytes, granulocytes and mast cells, provide the tumor with growth factors, angiogenic factors and enzymes for extracellular matrix (ECM) remodeling, which favor tumor progression and relapse. 46, 47 The PI3K family has important functions in both anti-tumoral and pro-tumoral immune cell subsets. 48 PI3Kd and PI3Kg are the major PI3K isoforms in leukocytes and regulate a number of processes required for maturation, activation, migration and function of both myeloid and lymphoid cells. PI3Kd and PI3Kg have non-redundant roles but synergize in activating and maintaining the response of immune cells to multiple extracellular signals. 48, 49 PI3Kd is involved in tumor immune surveillance, as it strictly controls full maturation and cytotoxic activity of NK cells and T lymphocytes. Zebedin et al. 50 report that absence of PI3Kd impairs degranulation of NK cells, preventing their cytotoxic activity against leukemic cells, thus favoring cancer aggressiveness. Similar degranulation defects have been observed in cytotoxic T lymphocytes of PI3Kd-deficient mice challenged with colon adenocarcinoma cells, 51 thus supporting the notion that loss of PI3Kd signaling impairs the efficacy of tumor immune surveillance. On the other hand, PI3Kd is also indispensable for maturation and survival of T regulatory (Treg) cells, which attenuate the T-cell-mediated response. 52, 53 Thus, in the tumor context, limiting Treg activity through the inhibition of PI3Kd could enhance tumor-suppressive immune reactions and represent a promising cancer treatment. Similar to Tregs, immature dendritic cells at the TME can produce signals that attenuate the immune response. 54 Noteworthy, the regulation of this process is mediated by the activation of PI3K downstream Toll-like receptors. 55 In cultured dendritic cells, Marshall et al.
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show that PI3Kb and d inhibitors can blunt the production of immune-modulators, such as interleukin (IL)-10 and transforming growth factor (TGF)-b, as well as enhance the secretion of factors that promote effector T-cell maturation. PI3K inhibition in vivo thus leads to increased T-cell-mediated tumor killing and rejection in three different murine models. Overall, these findings indicate that PI3Kd is involved in both pro-and anti-tumor immune processes and that cell-specific functions of PI3Kd should be carefully evaluated and eventually exploited to tailor a therapy that favors the anti-tumor response.
Although adaptive immunity and immune-surveillance protect from tumor development, chronic inflammation can have a critical role in tumor initiation. For example, chronic inflammation is shown by epidemiological studies in humans to correlate with higher risk of cancer and to promote several neoplasms such as pancreatic adenocarcinoma, hepatocellular carcinoma and colon cancer. 56 Noteworthy, in chronic inflammation, PI3K signaling mediates activation and function of monocytes, granulocytes and mast cells at multiple levels, ranging from migration to cytokine secretion. 57 PI3Ks are thus promising drug targets and, in agreement, PI3Kg inhibition suppresses the development of different chronic inflammatory diseases. [58] [59] [60] [61] In line with an impact on inflammation-promoted cancer development, mice lacking PI3Kg show reduced infiltration of immune cells and decreased multiplicity and size of colon neoplasms in a model of colitis-induced colon cancer. 62 This suggests that PI3Kg inhibition may act as a cancer preventive treatment in patients suffering from inflammatory bowel disease.
Inflammation is not only a tumor-initiating condition but also represents a response favoring cancer growth and progression. PI3K-dependent signaling can thus have a role in mounting a cancer-supporting immune reaction. 63 In line with this view, pharmacological or genetic blockade of PI3Kg impairs leukocyte recruitment at the TME and reduces tumor growth in multiple cancer models, including subcutaneous Lewis lung carcinoma (LLC), orthotopic pancreatic Panc02 and the spontaneous MMTVPyMT breast cancer tumor. 64 In these models, PI3Kg is activated in granulocytes and monocytes in response to tumor-released chemokines and cytokines, such as IL-8, SDF-1a (stromal cellderived factor 1a), IL-lb, IL-6, TNF-a and CSF1 (colony-stimulating factor-1). Upon activation, PI3Kg promotes extravasation and Figure 1 . Functional interplay between tumor and stromal PI3K signaling in cancer growth, survival and invasion. Tumorigenesis relies on an intricate network of interactions between cancerous and non-cancerous cells that is finely tuned by selected PI3K isoforms. PI3Ka is the most frequently mutated isoform in tumor cells and actively contributes to all steps of tumorigenesis, including tumor growth, tumor angiogenesis and metastatization. The functional cooperation between mutant PI3Ka (PI3Ka mut ) and bone marrowderived PI3Kg and PI3Kd is essential for tumor growth. On the other hand, tumor neo-vascularization requires the concomitant activation of tumor cell PI3Ka mut , leukocyte PI3Kg as well as endothelial PI3Ka and PI3K-CIIa. Finally, the cross-talk between PI3Ka mut in cancer cells and stromal PI3K contribute to the development of metastasis.
recruitment of monocytes and granulocytes to the TME by mediating the inside-out activation of the adhesion molecule integrin a4b1. 64, 65 Specifically, these results highlight a major role of PI3Kg in the recruitment of innate immune system cells. 62, 64 This is in line with other reports indicating that PI3Kg is a crucial regulator of innate immune cell chemotaxis, [66] [67] [68] while its role in adaptive immunity is minor and partially redundant with PI3Kd. 49, 69, 70 Overall, this portrays PI3Kg as an ideal target for cancer treatment, as the inhibition of this enzyme is expected to dampen tumor-supporting inflammation with minor perturbation of adaptive anti-cancer immune responses.
PI3K SIGNALING IN TUMOR ANGIOGENESIS
The ability of tumors to grow and invade strictly relies on the formation of new blood vessels that provide the adequate supply of nutrients and oxygen. Tumor neovascularization is coordinated by a plethora of cell types that either reside in or are recruited to TME. 71 Tumor cells provide the first cue for neoangiogenesis, as they secrete pro-angiogenic factors, such as the vascular endothelial growth factor (VEGF), that activate naturally quiescent endothelial cells. New blood vessels thereby originate from pre-existing vascular structures as a result of intensive proliferation and migration of activated endothelial cells. In addition, tumor infiltrating bone marrow-derived cells, including monocytes, mast cells and endothelial progenitor cells, can directly promote angiogenesis and vasculogenesis. 72 The PI3K signaling route is engaged in nearly all cellular components of TME and is therefore crucial for the fine-tuning of tumor neovascularization. Compelling evidence indicates that in transformed cells, PI3Ks control hypoxia-inducible factor (HIF)-1a-mediated expression and secretion of VEGF. [73] [74] [75] PI3K inactivation by expression of either PTEN or a dominant-negative mutant Akt suppresses HIF-1a and VEGF expression in prostate cancer xenografts, eventually reducing tumor angiogenesis and growth. 76 Similarly, the pan-PI3K inhibitor LY294002 blocks tumor vascularization by directly inhibiting VEGF expression and release from ovarian carcinoma cells. 77 Notably, downregulation of PI3Ka mimics the anti-angiogenic properties of LY294002, as PI3Ka siRNA decreases ovarian tumor angiogenesis and growth, via inhibition of HIF-1a/VEGF expression. 75 This evidence therefore suggests that targeting of PI3Ka could constitute an amenable strategy to prevent tumor-induced neovascularization.
In endothelial cells, PI3Ks positively affect angiogenesis by transducing signals downstream angiogenic receptors, such as members of the VEGFR family, including VEGFR-1/Flt-1, VEGFR-2/ KDR/Flk-1 and VEGFR-3.
78-80 Akt, in turn, mobilizes key molecules involved in endothelial cell migration, tubulogenesis and proliferation, like endothelial NO synthase and small GTPases RhoA and Rac1. 81, 82 Genetic models provide a proof-of-concept that targeting endothelial PI3K signaling may also constitute a promising therapy to tackle tumor angiogenesis. The endothelial cell-specific genetic deletion of all class IA PI3Ks results in acute embryonic lethality due to impaired angiogenesis and development of major vascular abnormalities, such as vessel enlargement, aneurisms and hemorrhages. 83 Interestingly, heterozygous mutants retain normal vascular function under physiological conditions, while showing vessel leakage, reduced vessel size and delayed tumor growth in human melanoma grafts. Treatment with the pan-PI3K/mTOR inhibitor, NVP-BEZ235, fully recapitulates the anti-angiogenic effects of class IA PI3K loss. NVP-BEZ235 significantly impairs VEGF-dependent vascularization in vivo 83, 84 and strongly diminishes microvessel permeability in mammary tumor grafts. 84 Of note, endothelial class I PI3K signaling occurs via isoform-selective mechanisms. 81 PI3Ka has emerged as the key class IA isoform involved in the angiogenic responses to VEGF-A, as either ubiquitous or endothelial cellspecific inactivation of PI3Ka severely impairs angiogenic sprouting and vascular remodeling. 81, 85 Accordingly, IPD-196 and HS-173, two novel PI3Ka inhibitors, significantly dampen VEGF-dependent angiogenesis and display potent anti-tumor activity. 86, 87 Conversely, PI3Kb is only marginally involved in VEGF-mediated signals. 81 Rather, it cooperates with PI3Kg in mediating angiogenic responses of endothelial cells to GPCR agonists, such as stromal cell-derived factor-1a, IL-8 and sphingosine-1-phosphate. 81, 82 Noteworthy is the recent finding Abbreviations: bFGF, basic fibroblast growth factor; CAF, cancer-associated fibroblast; CSF1, colony-stimulating factor-1; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; IL, interleukin; PI3K, phosphoinositide-3 kinase; SDF-1, stromal cell-derived factor 1; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. a PI3K isoform represents the specific isoenzyme that transduces the signal of the 'secreted signalling molecule' inside the 'receiving compartment' , PI3K means that no specific isoform has been yet determined.
that the less characterized class II PI3Ks can also contribute to VEGF-dependent angiogenesis, both in physiological and in pathological contexts. Global or endothelial cell-specific deletion of PI3KC2a is embryonic lethal, owing to defects in sprouting angiogenesis and vascular maturation. 88 The vessel abnormalities of PI3KC2a-deficient embryos stem from defective VEGFR internalization that, in turn, triggers defective endothelial cell migration, proliferation, tube formation and barrier integrity. In agreement, animals bearing inducible endothelial deletion of PI3KC2a display reduced post-ischemic hindlimb angiogenesis as well as impaired vascularization and growth of LLC-1 and B16-BL6 melanoma grafts. 88 PI3KC2a therefore constitutes an attractive target for future development of anti-cancer drugs.
PI3Ks also regulate angiogenesis when activated in immune cells. In myeloid cells, engagement of PI3Kg downstream Toll-like or tyrosine kinase receptors (TLR/IL-1R) promotes inside-out activation of integrin a4b1, leading to myeloid cell invasion into tumors and, in turn, to tumor angiogenesis, growth and progression. 64 Accordingly, tumor angiogenesis is significantly blunted by pharmacological inactivation of myeloid PI3Kg by a 3 week-treatment with isoform-selective inhibitors, such as TG100-115 and AS605240. 64 In addition, PI3Kg is critically involved in angiogenic processes mediated by bone marrowderived endothelial precursors. Loss of PI3Kg in endothelial progenitors impairs integrin signaling, causing reduced viability and, in turn, defective neovascularization and reperfusion after hindlimb ischemia. 89, 90 These observations thus conclusively support the notion that drugs simultaneously targeting cancerous, endothelial and myeloid PI3Ks may have potent anti-angiogenic and anti-tumor activity. Emblematic is the case of the pan-PI3K inhibitor ZSTK474 that, by targeting both endothelial PI3K signaling and PI3K-dependent VEGF secretion by cancer cells, significantly delays tumor growth in RFX-631 xenografts. 91 In addition, pan-PI3K inhibition by GDC-0941 normalizes tumor vasculature and in combination with classical chemotherapeutic agents, like doxorubicin, improves delivery of the drug, thus significantly impairing breast cancer growth. 92 Similarly, SF1126, an LY294002 prodrug carrying a RGDS motif that enhances the delivery of the active compound to the tumor vasculature, significantly augments the anti-cancer activity of taxotere in prostate cancer xenografts. 93 Finally, PI3Kd inhibition by IC486068 enhances apoptosis and reduces migration as well as tubule formation of endothelial cells following irradiation. Accordingly, pharmacological inactivation of PI3Kd in vivo potentiates radiation-induced endothelial cytotoxicity, eventually delaying vascularization and growth of LLC-1 and GL261 tumor grafts during irradiation therapy. 94 Overall, these findings suggest that PI3K blockade may synergize with conventional anti-cancer therapy.
PI3K SIGNALING IN ECM REMODELING
Cellular components of the TME are immersed in the ECM, a complex network of macromolecules that is intensively modified and remodeled during cancer progression. Pathogenic remodeling of ECM in the TME is mainly due to CAFs, that secrete ECM components and ECM-modifying enzymes. 95 CAFs appear to constitute a heterogeneous population of cells and their origin is still debated. The most widely accepted view is that CAFs are early developmental precursors that respond to signals derived from cancer cells. 96 Among these signals, some are PI3K-mediated, such as the hepatocyte growth factor, the epidermal growth factor (EGF) and the basic fibroblast growth factor (Table 1) . 97 It is thus conceivable that PI3K inhibition may prevent CAFs expansion and consequent setting of a tumor-supporting ECM.
Plasticity of the ECM is exploited by tumors during the multi-step process leading to the acquirement of more aggressive and invasive features. 98 ECM degradation promotes tissue invasion by removing the physical barriers that contain the tumor and prevents its migration towards vessels. The matrix metalloproteinase (MMP) family of proteases degrades ECM proteins and is often deregulated in cancer. Increasing evidence links PI3K/PTEN/AKT signaling pathway to the control of MMP production in normal and cancer cells. [99] [100] [101] [102] Moreover, binding of extracellular MMPs by cancer cells activates intracellular cascades that stimulate growth and migration. 103 MMP-14 is a membrane-anchored MMP (MT1-MMP) that can initiate cancer cell migration through direct interaction with CD44, a cell surface adhesion molecule. 104 In particular, MMP-14/CD44 binding results in activation of EGF receptor (EGFR) and downstream engagement of PI3K signaling pathway in cancer cells. Although mechanisms by which CD44 activates EGFR are not fully characterized, the ultimate activation of PI3K axis in MMP-14-dependent cascade is crucial for promoting tumor cell migration. 104 Another prerequisite for tumor invasion is the ability of cancer cells to grow independently of matrix anchorage. In normal epithelial cells, loss of matrix adhesion leads to metabolic stress characterized by reduced nutrient uptake and decreased ATP production, which culminate in various forms of programmed cell death with important anti-tumoral consequences. 105 In tumors, PI3K signaling downstream EGFR enables cancer cells to overcome detachment-induced metabolic stress and, in turn, prevents programmed cell death. 106 Intriguingly, tumor cells, growing in anchorage-independent conditions, are addicted to PI3K signaling and thus more sensitive to PI3K/mTOR inhibitors than matrix adherent cells. 107 Therefore, by promoting both anchorage-independent growth of tumor cells and oncogenic ECM remodeling, PI3Ks potentially represent interesting targets to block a significant number of basic responses leading to cancer cell dispersion (Figure 2 ).
PI3K SIGNALING IN METASTASIS
Tumor inflammation, neo-angiogenesis and matrix remodeling are interconnected processes that eventually contribute to the endstage of tumorigenesis represented by tumor dissemination.
Beside intense TME remodeling, metastasis is a multi-stage process involving cancer cell motility out of the primary tumor, intravasation into the circulatory system, transit in the blood or lymph, extravasation and proliferation at a new distant site. 108 In Figure 2 . PI3K signaling in ECM remodeling and invasion. Stromal cells are inter-dispersed in the ECM, a highly organized network of macromolecules that are mainly secreted by CAFs and tumor cells. The functional interplay between tumor and TME cells triggers an intensive ECM remodeling that is an essential prerequisite for tumor invasion. PI3Ks favor cytokine-induced production of MMPs, a family of enzymes that degrade ECM proteins, both in cancer and stromal cells, thus allowing tumor cells to evade the physical barrier of tumors. In addition, cancer cell-intrinsic PI3K signaling promotes the EMT process that relinquishes tumor cells from intrinsic polarization and adhesion to the ECM, further contributing to tumor cell dissemination.
PI3K in cancer and stroma E Hirsch et al cancers of epithelial origin, these processes are favored by epithelial-to-mesenchymal transition (EMT), a developmental regulatory program that relinquishes tumor cells from intrinsic polarization and adhesion to the ECM, eventually facilitating the rise of satellite lesions. 109 EMT is coordinated by a set of pleiotropically acting transcriptional factors, such as Snail, Slug, Twist and Zeb1/2. 110 For example, Twist promotes loss of E-cadherin-mediated cell-cell adhesion and induces cell motility. 111 Interestingly, the PI3K pathway is involved in this process as Akt2 is a target of Twist-mediated transcriptional regulation. 112 On the other hand, Twist is directly phosphorylated and activated by Akt, thus indicating the presence of a potential positive feedback loop that, relying on PI3K signaling, promotes EMT. 113 In line with this view, active Twist induces its transcriptional target TGF-b2, leading to enhanced TGF-b receptor signaling, which in turn maintains a hyperactive PI3K/Akt axis in breast cancer cells. 113 According to these findings, overexpression of activated mutants of Akt can promote EMT in squamous cell carcinoma lines. 114 In further agreement, knock-in in the PIK3CA gene of the hotspot activating mutation H1047R in a non-tumorigenic human breast epithelial cell line like MCF10A cells results in marked EMT and increased invasive phenotype, compared with isogenic wild-type cells. 115 These studies in cell culture are paralleled by gene profiling in primary tumors, as a recent transcriptional profile of endometrial carcinomas reports an association between EMT and PI3K activation into ERa negative tumors, thus providing a rational for clinical trials exploring the effects of PI3K/mTOR and EMT inhibitors. 116 However, careful patient stratification appears critical as a robust 76-gene EMT signature in non-small cell lung cancer has been found to predict resistance to PI3K inhibition.
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PI3K INHIBITORS: ATTACK ON MULTIPLE FRONTS
The various roles of PI3K-mediated signaling in the cross-talk between the tumor and its microenvironment clearly indicate a therapeutic potential. However, the identification of strategies aimed at blocking oncogenic PI3K signaling without affecting important systemic functions is still a challenge. Inhibition of all PI3Ks causes a potent blockade of the pathway and thus appears attractive, as it can concomitantly hit the tumor in its weak points. However, systemic toxicity of pan-PI3K inhibitors represents a major drawback. As different PI3K isoforms have different expression patterns and activation mechanisms, inhibition of specific PI3K isoforms in defined tumors appears a way to circumvent toxicity issues. An example is the recent success of the PI3Kd-specific inhibitor CAL-101 in the treatment of B-cell lymphoid malignancies. 118 These promising effects are likely due to the concomitant action of the drug in both tumor and TME. For example, in leukemic B cells, PI3Kd blockade impairs pro-survival signaling and induces tumor cell death. On the other hand, inhibition of PI3Kd in monocyte-derived cells of the lymph node stroma blocks the secretion of pro-survival chemokines sensed by tumor cells and strengthens the pro-apoptotic effect of the drug. 119 The specificity of such effects is further ensured by the PI3Kd expression pattern: as this enzyme is mainly expressed in bone marrow-derived cells, the effects of the drug do not spread to off-target organs. The same concept could be applied to PI3Kg-specific inhibitors. Mouse models show that these drugs effectively dampen tumor-promoting inflammation. Therefore, their use might be particularly attractive in the therapy of pancreatic cancer where PI3Kg can be found overexpressed 36 and where inflammation has a critical role in resistance to chemotherapy. 120 Another attractive example is selective PI3Ka inhibition: blockade of this isoform could be exploited in solid tumors to block growth of cancer cells carrying PIK3CA mutant alleles as well as to restrain tumor angiogenesis. In addition, potential redundancy in class IA isoforms might limit side effects, such as abnormal control of glucose homeostasis.
CONCLUSION AND FUTURE PERSPECTIVES
In summary, the PI3K signaling pathway is equally active in cancer cells as well as in the major components of the TME and controls not only tumor growth but also tumor-associated immune responses, tumor angiogenesis, tumor-induced ECM reorganization and tumor dissemination. The ability of PI3Ks to promote tumorigenesis by acting both in 'seed' and 'soil'-dependent mechanisms indicates that therapeutic PI3K inhibition can be envisioned as a unique opportunity to attack the tumor on multiple fronts. So far, phase I clinical trials with PI3K inhibitors addressed tolerability and focused on tumor shrinkage as an end point in set of patients with advanced disease. 5 Although this evidenced clinical response and significant reduction in tumor size in selected patients, this has not allowed to evaluate the potential anti-metastatic effect of PI3K inhibition. New phase II clinical trials will eventually test this hypothesis and potentially provide new weapons to fight disease progression.
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